BioSpace News Archive

Marrone Bio Innovations, Inc., an international leader in sustainable bioprotection and plant health solutions, and Vive Crop Protection, a leader in Precision Chemistry solutions and owner of the patented Allosperse® technology, announced an agreement that will provide a suite of ground-breaking products for U.S. growers that combine a leading biological with proven conventional chemistry utilizing the unique Allosperse Delivery System.

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that it has significantly strengthened its Intellectual Property (IP) portfolio as European Patent Application No. 14851547.1 has been granted.

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months ended June 30, 2020 and highlighted recent corporate progress. Recent Corporate Progress Acquisition of Tetraphase Pharmaceuticals, Inc.: On July 28, 2020, La

Carestream Health has launched its DRX-Compass X-ray System for mid-tier hospitals and medical imaging centers worldwide.

Record Quarter for Consumer Brands with 3X Revenue Growth Lowest Cash Operating Expenses in Five Quarters $200 Million Private Placement Significantly Reduced Debt and Debt Servicing Expense [06-August-2020] EMERYVILLE, Calif. , Aug. 6, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and B

New focus on justice through equity in diverse clinical trials, STEM education and expanding entrepreneurship to undeserved communities will drive nation’s largest life science advocacy organization

Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40 th Annual Growth Conference

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that on August 5, 2020, the Company completed the submission of its Biologics License Application (“BLA”) under the FDA’s Rolling Review process for omburtamab. Omburtamab is an investigational, m

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced updates related to the company’s commitment to the amyotrophic lateral sclerosis (ALS) community, in celebration of the third anniversary of the U.S. availability of RADICAVA ® (edaravone).

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, announced today that Cleveland Clinic has joined GRAIL’s PATHFINDER Study, a prospective, multi-center clinical study that is evaluating the implementation of Galleri™, an investigational multi-cancer early detection blood test, into clinical practice for the first time.